2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

endocrine and metabolic diseases

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1051
    Flumethasone
    1 Publications Verification

    Flumetasone

    		 Glucocorticoid Receptor TNF Receptor Interleukin Related Keap1-Nrf2 Inflammation/Immunology Endocrinology Cancer
    Flumethasone (Flumetasone) is an orally active, high selective and potent glucocorticoid receptor (GR) agonist. Flumethasone activates GR to inhibit nuclear factor kappa B (NF-κB)-mediated pro-inflammatory cytokine production (TNF-α, IL-1β) and promotes anti-inflammatory gene expression (IL-10), while also regulating metabolic enzyme activity (tyrosine aminotransferase induction). Flumethasone is promising for research of inflammatory diseases, cancer, and endocrine regulation .
    Flumethasone
  • HY-P1723
    Spexin
    1 Publications Verification

    Neuropeptide Q

    		 Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy Cardiovascular Disease Neurological Disease
    Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
    Spexin
  • HY-P991504
    LAE-102

    		Anaplastic lymphoma kinase (ALK) TGF-β Receptor TGF-beta/Smad Metabolic Disease Endocrinology Cancer
    LAE-102, a monoclonal antibody, is an activin receptor type II-A (ACTRIIA/ACVR2) antagonist. LAE-102 is promising for research of endocrine and metabolic diseases, tumors, and respiratory system diseases .
    LAE-102
  • HY-106938
    Eldacimibe

    WAY-ACA 147

    		 Acyltransferase Cardiovascular Disease Metabolic Disease
    Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
    Eldacimibe
  • HY-160168
    BTK-IN-31

    		Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-167680
    Denagliptin

    GSK823093

    		 Endogenous Metabolite Metabolic Disease
    Denagliptin (GSK823093) is a small molecule dipeptidyl peptidase IV (DPP-4) inhibitor with activity for the suppression of endocrine and metabolic diseases. Denagliptin can be used to study type 2 diabetes. Denagliptin is stable in the solid state but degrades in solution and in mixtures with various excipients. Denagliptin also exhibits degradation in capsules, mainly through cyclization reactions to form (3S,7S,8aS) aminoamines to provide further synthetic materials. The degradation pathway of Denagliptin was elucidated, providing data to support its formulation development and regulatory filings .
    Denagliptin
  • HY-P1723A
    Spexin TFA

    Neuropeptide Q TFA

    		 Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy Cardiovascular Disease Metabolic Disease
    Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
    Spexin TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: